LifeTech Scientific Corporation (HK:1302)
:1302
Want to see HK:1302 full AI Analyst Report?
Top Page
LifeTech Scientific Corporation
(1302)
Select Model
Select Model
Rating:61Neutral
Price Target:
HK$1.50
▼(-5.06% Downside)
Action:Reiterated
Date:05/27/26
The score is primarily supported by strong recent revenue growth and an exceptionally low-debt balance sheet. It is held back by a weak technical setup (trading below major moving averages with subdued RSI) and a demanding valuation (P/E ~42), alongside recent multi-year margin and ROE compression.
Positive Factors
Revenue re-acceleration
A 50.9% revenue rebound in 2025 signals renewed demand for the company’s interventional devices and stronger commercial traction. Durable top-line momentum supports sustained investment in sales, clinical adoption, and scale benefits that can improve long-term unit economics and market share.
Negative Factors
Material margin compression
Sustained and large margin decline implies rising cost structure or pricing pressure that erodes earnings power. Lower margins reduce internal funds for R&D and commercial expansion, weaken resilience to revenue shocks, and make profitability more sensitive to procedural volume changes.
Read all positive and negative factors
Positive Factors
Negative Factors
Revenue re-acceleration
A 50.9% revenue rebound in 2025 signals renewed demand for the company’s interventional devices and stronger commercial traction. Durable top-line momentum supports sustained investment in sales, clinical adoption, and scale benefits that can improve long-term unit economics and market share.
Read all positive factors
LifeTech Scientific Corporation (1302) vs. iShares MSCI Hong Kong ETF (EWH)
Market Cap
HK$6.52B
Dividend YieldN/A
Average Volume (3M)26.58M
Price to Earnings (P/E)41.1
Beta (1Y)0.90
Revenue Growth5.10%
EPS Growth-32.48%
CountryHK
Employees1,395
SectorHealthcare
Sector Strength45
IndustryMedical - Devices
Share Statistics
EPS (TTM)0.03
Shares Outstanding4,631,712,400
10 Day Avg. Volume33,345,600
30 Day Avg. Volume26,582,987
Financial Highlights & Ratios
PEG Ratio-1.21
Price to Book (P/B)1.79
Price to Sales (P/S)4.58
P/FCF Ratio12.52
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)0.08
Revenue Forecast (FY)HK$1.53B
LifeTech Scientific Corporation Business Overview & Revenue Model
Company Description
LifeTech Scientific Corporation, an investment holding company founded in 1999 and based in Shenzhen, People's Republic of China, focuses on the research, production, and distribution of interventional medical devices. These advanced technologies ...
How the Company Makes Money
The company primarily makes money by selling medical devices used in minimally invasive interventional procedures to hospitals and healthcare providers, generating revenue from the commercialization of its proprietary device portfolio. Revenue is ...
LifeTech Scientific Corporation Financial Statement Overview
Summary
Income Statement
58
Neutral
Balance Sheet
86
Very Positive
Cash Flow
62
Positive
| Breakdown | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 1.37B | 1.30B | 1.27B | 1.10B | 925.33M |
| Gross Profit | 1.02B | 981.43M | 995.64M | 873.93M | 747.53M |
| EBITDA | 291.74M | 271.87M | 253.46M | 445.78M | 397.59M |
| Net Income | 147.83M | 222.39M | 263.24M | 325.34M | 292.47M |
Balance Sheet | |||||
| Total Assets | 5.01B | 4.90B | 4.70B | 3.69B | 3.18B |
| Cash, Cash Equivalents and Short-Term Investments | 1.20B | 1.18B | 1.18B | 833.79M | 1.48B |
| Total Debt | 8.04M | 4.98M | 9.30M | 9.67M | 15.67M |
| Total Liabilities | 1.48B | 1.42B | 1.37B | 769.05M | 653.61M |
| Stockholders Equity | 3.51B | 3.49B | 3.37B | 2.90B | 2.50B |
Cash Flow | |||||
| Free Cash Flow | 501.49M | 38.46M | 125.36M | 52.84M | 145.57M |
| Operating Cash Flow | 555.01M | 321.46M | 418.05M | 388.32M | 488.85M |
| Investing Cash Flow | -73.91M | -517.53M | -453.88M | -458.47M | -86.76M |
| Financing Cash Flow | -383.59M | -116.97M | 182.71M | -215.20M | -256.38M |
LifeTech Scientific Corporation Technical Analysis
Negative
1.58
Price Trends
1.88
Negative
1.79
Negative
1.83
Negative
Market Momentum
-0.11
Positive
33.54
Neutral
12.47
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HK:1302, the sentiment is Negative. The current price of 1.58 is below the 20-day moving average (MA) of 1.69, below the 50-day MA of 1.88, and below the 200-day MA of 1.83, indicating a bearish trend. The MACD of -0.11 indicates Positive momentum. The RSI at 33.54 is Neutral, neither overbought nor oversold. The STOCH value of 12.47 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for HK:1302.
LifeTech Scientific Corporation Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
70 Neutral | HK$6.10B | 15.45 | 12.01% | 1.26% | 10.19% | 23.70% | |
65 Neutral | HK$6.20B | 28.61 | 10.38% | 1.50% | 3.83% | -27.04% | |
61 Neutral | HK$6.52B | 41.10 | 4.06% | ― | 5.10% | -32.48% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
48 Neutral | HK$12.67B | 28.57 | 6.07% | ― | -3.62% | ― | |
44 Neutral | HK$2.72B | -11.40 | -11.27% | ― | 16.35% | 9.84% | |
41 Neutral | HK$1.53B | -0.81 | -7.01% | ― | -4.38% | ― |
* Healthcare Sector Average
HK:1302
LifeTech Scientific Corporation
1.51
-0.48
-24.12%
HK:0853
MicroPort Scientific
6.61
-1.63
-19.78%
HK:9996
Peijia Medical Ltd.
4.04
-2.27
-35.97%
HK:1789
AK Medical Holdings Ltd.
5.43
-0.51
-8.59%
HK:2160
MicroPort CardioFlow Medtech Corp.
1.20
-3.05
-71.76%
HK:2172
MicroPort NeuroTech Limited
10.60
-2.28
-17.70%
LifeTech Scientific Corporation Corporate Events
LifeTech Strengthens Board Independence With Re-designation of Veteran Director
Jun 18, 2026
LifeTech Scientific Corporation has redesignated long-serving non-executive director Jiang Feng as an independent non-executive director, effective 18 June 2026. Jiang, a veteran of China’s medical device industry with extensive leadership r...
LifeTech Scientific Sets Out Board Composition and Committee Structure
Jun 18, 2026
LifeTech Scientific Corporation has detailed the current composition of its board of directors, confirming a structure that includes three executive directors and three independent non-executive directors, with Chairman and Chief Executive Officer...
LifeTech Scientific Shareholders Approve All AGM Resolutions and Renew Capital Mandates
May 28, 2026
LifeTech Scientific Corporation reported that all resolutions proposed at its 28 May 2026 annual general meeting were passed by shareholders via poll, including adoption of the 2025 audited financial statements, re-appointment of its external audi...
LifeTech Scientific Reshapes Board as Two Executive Directors Step Down
May 22, 2026
LifeTech Scientific Corporation announced that executive directors Liu Jianxiong and Feng Xiaoling have resigned from the board, with Liu stepping down as an authorised representative and Feng leaving the nomination committee so they can devote mo...
LifeTech Scientific Updates Board Composition and Committee Roles
May 22, 2026
LifeTech Scientific Corporation has updated the market on the composition of its board of directors, confirming Xie Yuehui as executive director, chairman and chief executive officer, alongside executive directors Wu Liping and Fang Yu, non-execut...
LifeTech to Acquire 96.46% of Starway Medical via US$274 Million Convertible Bond Deal
May 22, 2026
LifeTech Scientific Corporation has agreed to acquire approximately 96.46% of Beijing-based Starway Medical Technology, Inc., valuing the target at about RMB1.942 billion, using a price-to-earnings multiple of 18 times Starway’s 2025 net pro...
LifeTech Scientific Sets 2026 AGM to Renew Board, Auditor and Share Issuance Mandate
May 6, 2026
LifeTech Scientific Corporation has convened its annual general meeting for 28 May 2026 in Shenzhen, where shareholders will review and adopt the audited consolidated financial statements for the year ended 31 December 2025 and the associated dire...
LifeTech Seeks More Time to Restore Independent Board Compliance
Apr 24, 2026
LifeTech Scientific Corporation, a Cayman Islands-incorporated issuer listed in Hong Kong, is governed by a board that includes executive, non-executive and independent non-executive directors, who also serve on the audit, nomination and remunerat...
LifeTech Scientific Delivers Revenue Growth but Profit Hit by Non-Recurring Charges in 2025
Mar 31, 2026
LifeTech Scientific Corporation, a Hong Kong-listed medical device maker specializing in cardiovascular and endovascular products such as stent grafts, reported modest top-line growth for 2025 driven primarily by higher stent graft sales. The grou...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.